SEC Form S-8 POS filed by Aerie Pharmaceuticals Inc.

As filed with the Securities and Exchange Commission on November 21, 2022

 

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Post-Effective Amendment No. 1 to:

 Form S-8 Registration Statement No.: 333-192030

 

UNDER

THE SECURITIES ACT OF 1933

---

AERIE PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

---

4301 Emperor Blvd., Suite 400

Durham, North Carolina 27703

(Address of Principal Executive Offices, Including Zip Code)

 

AERIE PHARMACEUTICALS, INC. 2005 STOCK OPTION PLAN

AERIE PHARMACEUTICALS, INC. OMNIBUS INCENTIVE PLAN

AERIE PHARMACEUTICALS, INC. EMPLOYEE STOCK PURCHASE PLAN

 (Full Title of the Plan)

 

Royce Bedward

Senior Vice President, General Counsel

Aerie Pharmaceuticals, Inc.

6201 South Freeway

Fort Worth, Texas 76134

(817) 293-0450

(Name, address and telephone number, including area code, of agent for service)

 

Copies to:

 

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

---

EXPLANATORY NOTE — DEREGISTRATION OF SECURITIES

 

This Post-Effective Amendment relates to the following Registration Statement on Form S-8 (the “Registration Statement”), originally filed with the Securities and Exchange Commission (the “SEC”) by Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”):

 

 

Pursuant to the Agreement and Plan of Merger, dated as of August 22, 2022, among the Registrant, Alcon Research, LLC (“Parent”), and Lyon Merger Sub, Inc. (“Merger Sub”),  Merger Sub merged with and into the Registrant (the “Merger”) on November 21, 2022, with the Registrant becoming a wholly-owned subsidiary of Parent as of the effective time of the Merger.   At the effective time of the Merger, each outstanding share of common stock of the Registrant was converted into the right to receive $15.25 in cash (in the case of outstanding stock options, less the exercise price for the applicable shares of common stock underlying the stock option), without interest and subject to required withholding taxes.

 

As a result of the Merger, the Registrant has terminated all offerings of the Registrant’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statement.  In accordance with undertakings made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that have been registered for issuance that remain unsold at the termination of the offering, the Registrant hereby removes from registration all of such securities of the Registrant registered but not sold or otherwise issued under the Registration Statement, if any, as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statement.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on November 21, 2022.

 

No other person is required to sign this Post-Effective Amendment to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

---